



Company Contact:
Richard Gabriel
CEO and President
941 366-3400

-or-

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

FOR IMMEDIATE RELEASE:

**DNAPRINT PHARMACEUTICALS / HARVARD MEDICAL
SCHOOL STUDY SHOWS WHY PT-401 IS ‘SIGNIFICANTLY’
MORE EFFECTIVE THAN EPOETIN**

SARASOTA, Fla., June 26, 2007 – DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the results of a new study conducted to understand the binding of PT-401 and Epoetin to the EPO receptor in an attempt to explain why the Company’s proprietary PT-401 protein is ‘significantly’ more effective than another prevalent drug, epoetin, in raising red blood cell counts.

The study revealed that less PT-401 is bound to the receptor and less is inactivated (inactivation is mostly done by a receptor-mediated clearance mechanism) resulting in a prolonged half-life. This binding feature of PT-401 explains the superior *in vivo* activity, implying important beneficial effects in patients. The study was presented by Dr. Sytkowski as part of the Annual Meeting of the European Renal Association in Barcelona, Spain, on June 23, 2007.

The experiments were conducted by the Company and Dr. Arthur Sytkowski, the Director of the Laboratory for Cell and Molecular Biology at Beth Israel Deaconess Medical Center (BIDMC) in Boston, an affiliate of the Harvard Medical School.

“Dr. Sytkowski is one of the foremost scientists in the field of therapeutic protein research, particularly Erythropoietin,” stated DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. “This study brings us one step closer to the day that PT-401, which in our studies appears to be superior to epoetin, may be available to benefit dialysis patients who suffer from anemia. DNAPrint® Pharmaceuticals looks forward to continuing our collaboration with Dr. Sytkowski on this important project.”

PT-401 is a “Super EPO,” a more powerful erythropoiesis stimulating agent than Erythropoietin, a well-known drug used for the treatment of anemia. Previously, DNAPrint Pharmaceuticals, the Company’s wholly owned subsidiary announced three successful milestones related to PT-401: the use of CHO cell lines, the use of SDS-PAGE, a well-established separation technique for the testing of cell lines, and a specially developed isoelectric focusing (IEF) method. The initial research has been conducted in conjunction with Dr. Sytkowski.

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.

(MORE)

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

##